Sight Sciences’ core business model relies on innovative interventional eyecare devices primarily serving glaucoma and dry eye markets. The Surgical Glaucoma segment generates the majority of revenue and benefits from clinical differentiation, though reimbursement challenges and competitive MIGS ma…
Sight Sciences (SGHT) Q4 2024: Surgical Glaucoma Revenue Up 9% Amid Market Headwinds, Dry Eye Reimbursement Progress
Sight Sciences navigated a complex micro-invasive glaucoma surgery (MIGS) market in Q4 2024, delivering modest revenue growth in its core surgical glaucoma segment despite Medicare reimbursement restrictions. The company advanced its dry eye disease reimbursement strategy, positioning for a potential market inflection in 2025. Operational discipline reduced cash burn significantly, supporting continued investment in innovation and commercial expansion.
Summary
- Market Adaptation: SGHT managed MIGS reimbursement headwinds while maintaining surgeon engagement and account growth.
- Dry Eye Reimbursement Momentum: Progress toward equitable payer coverage for TearCare signals a potential growth catalyst.
- Financial Discipline: Significant reduction in cash usage underpins investments in pipeline and market development.
Business Overview
Sight Sciences develops interventional eyecare technologies targeting glaucoma and dry eye disease, two large, underserved markets. The company generates revenue primarily through its Surgical Glaucoma segment, featuring the OMNI® Surgical System, and its Dry Eye segment, centered on the TearCare® System. These segments address distinct but complementary clinical needs with minimally invasive or non-invasive procedures designed to improve patient outcomes and reduce reliance on medication.
Performance Analysis
In the fourth quarter of 2024, Sight Sciences reported total revenue of $19.1 million, marking a 2% increase year-over-year driven by a 9% rise in surgical glaucoma revenue to $18.8 million. This growth reflected a 7% increase in ordering accounts and a 6% rise in account utilization compared to the prior year, despite sequential utilization declines influenced by new Medicare Local Coverage Determinations (LCDs) restricting multiple MIGS procedures during cataract surgery. The dry eye segment revenue declined sharply to $0.3 million from $1.6 million, as the company shifted focus from cash-pay sales to establishing reimbursed market access for TearCare.
Gross margin improved to 87% from 85% year-over-year, primarily due to a favorable product mix weighted toward higher-margin surgical glaucoma products. However, surgical glaucoma gross margin slightly declined to 87% from 88% due to product mix shifts, while dry eye gross margin decreased to 51% from 53% due to lower production volumes and higher overhead per unit. Operating expenses rose modestly by 5% to $28.5 million, driven by increased personnel costs and research and development (R&D) spending, which grew 25% year-over-year in Q4. Adjusted operating expenses increased 9% to $24.4 million. The net loss widened slightly to $11.8 million, or $0.23 per share.
- Segment Dynamics: Surgical glaucoma growth offset by dry eye revenue decline amid strategic reprioritization.
- Margin Trends: Product mix and volume effects led to mixed margin outcomes across segments.
- Expense Management: Controlled operating expense growth reflects investments aligned with strategic priorities.
For the full year 2024, revenue totaled $79.9 million, down 1% from 2023, with surgical glaucoma revenue up 2% and dry eye revenue down 40%. The company reduced cash used by 62% to $17.8 million, reflecting operational discipline and working capital improvements, and ended the year with $120.4 million in cash and $40 million in debt.
Executive Commentary
"We experienced an increase in surgical glaucoma ordering accounts, and revenue both sequentially and compared to the fourth quarter of 2023, as well as account re-engagement momentum. We also made advancements towards our goal of achieving equitable market access for our TearCare technology with an increased number of claims reimbursed under commercial plans."
Paul Bedali, Co-founder and Chief Executive Officer
"Surgical glaucoma revenue fell short of our expectations, primarily due to the new Medicare LCD's effective mid-quarter, which had a more pronounced impact than expected. We generated $18.8 million in surgical glaucoma revenue, up 9% year-over-year, driven by ordering accounts and utilization increases, though utilization decreased sequentially."
Allie Ballerline, Chief Financial Officer
Strategic Positioning
1. Navigating MIGS Market Disruption
New Medicare LCDs eliminated coverage for multiple MIGS procedures during cataract surgery, reducing total claims by approximately 15%. Sight Sciences responded by focusing on surgeon education, emphasizing OMNI’s comprehensive efficacy and safety profile, and developing the standalone pseudophakic MIGS market segment, which is not subject to these restrictions. The company aims to convert more surgeons to an interventional mindset, leveraging compelling three-year clinical data to support OMNI’s role in delaying invasive glaucoma surgeries.
2. Advancing Dry Eye Reimbursement
With dry eye revenue down due to a strategic shift from cash-pay to reimbursement focus, Sight Sciences is actively engaging payers to establish equitable coverage for TearCare. The recently published Budget Impact Analysis demonstrated potential cost savings to payers, complementing strong clinical evidence from the Sahara randomized controlled trial. Although reimbursement policies remain in early stages, the company anticipates initial positive coverage decisions in 2025, which could unlock significant market growth given TearCare’s established installed base and procedure volume.
3. Product Innovation and Pipeline Development
The upcoming launch of OmniEdge in the first half of 2025 represents an iterative advancement designed to increase viscoelastic delivery with enhanced safety and reproducibility. This product expansion reflects Sight Sciences’ commitment to meeting diverse physician preferences and patient needs within the evolving MIGS landscape. The company plans to continue leveraging its innovative platform to maintain competitive leadership amid new market entrants.
4. Financial Discipline Enabling Growth Investment
Significant reductions in cash burn and disciplined expense management have strengthened Sight Sciences’ financial position. The company expects adjusted operating expenses to increase modestly in 2025 to support market development in standalone surgical glaucoma, TearCare reimbursement efforts, and R&D. This balanced approach aims to sustain innovation while navigating market headwinds.
5. Commercial Execution and Market Expansion
Sight Sciences is re-engaging accounts post-LCD clarity, growing ordering accounts, and enhancing utilization through targeted education and competitive strategies. The dry eye commercial infrastructure covers over 1,500 eye care facilities with more than 65,000 TearCare procedures performed, positioning the company to scale rapidly upon reimbursement wins. International market development and expanded surgeon certification remain additional growth avenues.
Key Considerations
Sight Sciences’ Q4 results illustrate the challenges and opportunities inherent in a transforming eyecare market. The company’s core surgical glaucoma business remains resilient despite regulatory headwinds, while the dry eye segment is positioned for a potential inflection pending reimbursement progress.
Key Considerations:
- Regulatory Impact on MIGS: Medicare LCD restrictions significantly reduced multi-procedure claims, pressuring near-term utilization but creating clarity for market adaptation.
- Interventional Mindset Shift: Education and clinical evidence are critical to expanding standalone MIGS adoption beyond combination cataract procedures.
- Reimbursement as Growth Lever: TearCare’s transition from cash-pay to reimbursed treatment is pivotal for unlocking the multi-billion-dollar dry eye market.
- Innovation Pipeline: Incremental product advancements such as OmniEdge support differentiation and long-term leadership in MIGS.
- Financial Stability: Reduced cash burn and strong liquidity provide flexibility to invest in strategic initiatives despite market uncertainties.
Risks
Key risks include ongoing uncertainty around the timing and extent of reimbursement coverage for TearCare, potential competitive pressures from new MIGS entrants, and tariff-related cost increases impacting gross margin. The evolving regulatory environment for MIGS procedures also poses risks to near-term revenue growth. Additionally, the outcome and timing of the pending patent infringement case against Alcon remain uncertain and could affect future cash flows.
Forward Outlook
For Q1 2025, Sight Sciences expects revenue to decline low to mid double digits year-over-year, reflecting the full impact of Medicare LCD restrictions on multiple MIGS procedures. Full-year 2025 revenue guidance ranges from $70 million to $75 million, representing a 6% to 12% decline compared to 2024, primarily due to these reimbursement headwinds and conservative assumptions regarding dry eye reimbursement wins.
- Adjusted operating expenses are expected to increase 4% to 6% to $105 million to $107 million, reflecting investments in standalone surgical glaucoma market development, TearCare market access, and R&D.
- Dry eye revenue is forecasted at approximately $1 million for 2025, excluding potential upside from reimbursement achievements.
Management emphasizes continued focus on surgeon education, reimbursement strategy execution, and product innovation to navigate the challenging environment and position for growth beyond 2025.
Takeaways
Investors should note that Sight Sciences is actively managing a transitional period in the MIGS market, balancing regulatory challenges with strategic investments in education and product development.
- Market Resilience Amid Headwinds: Despite Medicare restrictions, surgical glaucoma revenue growth and account expansion demonstrate underlying demand and effective commercial execution.
- Reimbursement as a Critical Catalyst: TearCare’s reimbursement progress is a key inflection point, with clinical and economic data supporting future coverage that could unlock substantial dry eye market potential.
- Long-Term Growth Drivers: The standalone MIGS market development, OmniEdge launch, and sustained R&D investment position the company for recovery and expansion as market dynamics stabilize.
Conclusion
Sight Sciences delivered a mixed but strategically significant Q4 2024, showing resilience in surgical glaucoma and laying groundwork for dry eye reimbursement. The company’s disciplined financial management and innovation pipeline provide a foundation to navigate near-term headwinds and capitalize on long-term market opportunities.
Industry Read-Through
The evolving reimbursement landscape for MIGS procedures underscores a broader industry trend of regulatory tightening affecting device utilization and revenue models. Companies in the eyecare technology sector must balance innovation with payer engagement and surgeon education to sustain growth. The dry eye disease segment exemplifies a shift toward procedural interventions backed by robust clinical and economic evidence to secure reimbursement, a model that may influence adjacent therapeutic areas. Tariff impacts on manufacturing highlight ongoing supply chain vulnerabilities affecting medical device margins across the industry.